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Introduction
Our Coagulation Disorders Unit was founded 20 years 
ago. The unit is a tertiary care center within the Helsinki 
University Hospital, combining clinical and coagulation 
laboratory services and serving the Helsinki and Uusimaa 
Hospital District. The unit handles consultation cases for 
severe thrombosis and/or bleeding tendency, also offering 
consultation services nationwide. While hemophilias, von 
Willebrand disease and other bleeding disorders constitute 
the major part of patient visits to the clinic, thrombosis and 
consultations regarding the safe use of anticoagulants are 
frequent and increasing (Figure 1). In a population of around 
2 million inhabitants, more than 900,000 coagulation 
tests, of which 60% represent INR, were performed in our 
laboratories (HUSLAB) in 2018.
When the direct oral anticoagulants (DOACs) became 
available from 2008 onwards, initially, we were not 
confident on the overall safety of these new drugs, in 
the absence of the monitoring of the drug effect. In the 
phase III trials of the DOACs, relevant patient groups, 
such as patients with kidney or liver failure, patients 
having antiplatelet therapy, patients encountering bleeds 
and patients with active malignancy were excluded (1). 
Nevertheless, questions regarding anticoagulation of these 
vulnerable patients are often encountered, and we could not 
recommend DOACs for these patients at this early stage. 
We also, to increase the national awareness, authored an 
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article in the Finnish Medical Society Journal to encourage 
rational introduction of these new drugs (2), and national 
web-based guidelines have been gathered (accessible at 
www.hematology.fi, in Finnish). We were the first to set up 
specific laboratory assays for DOACs in our country, for 
dabigatran in 2011, for rivaroxaban in 2012 and for apixaban 
in 2015. In original studies, we have found that dabigatran 
may even paradoxically increase thrombin generation (TG) 
in certain situations, while rivaroxaban and apixaban differ 
in their TG response, mirroring the increasing DOAC 
concentration—i.e., once- vs. twice-daily dosing (3,4).
DOACs are gaining new indications, rivaroxaban for 
prevention of atherothrombosis in coronary artery disease, 
and several DOACs are being considered in cancer patients 
as well (5-7). While the use of DOACs is increasing, 
clinicians will encounter many patients switching from 
traditional vitamin K antagonists (VKAs) to DOACs, 
and broad education is required (8). To respond to the 
challenge of increased repertoire of anticoagulants in 
patients with risk factors for both thrombosis and bleeding, 
e.g., elderly patients undergoing vascular surgery, a special 
anticoagulation clinic was launched in conjunction with 
the Coagulation Disorders Unit in 2015. One physician 
and a registered nurse have the primary responsibility of 
responding to clinical consultations in anticoagulation-
related questions in both in- and out-patient settings. A 
warfarin self-management program was launched as well in 
collaboration with the laboratory at that time, to provide 
warfarin guidance and establishing safe therapy in patients 
with mechanical valvular replacement.
Oral anticoagulants
Direct oral anticoagulants
Dabigatran was the first DOAC to come on market, 
for thromboprophylaxis after orthopedic surgery with 
European Medicines Agency (EMA) approval in 2008. 
Orally administered direct factor Xa inhibitors (FXaI) 
include rivaroxaban, apixaban, edoxaban and betrixaban 
(but not in the EU for the last agent). At present, the 
indications for DOACs dabigatran, rivaroxaban and 
apixaban include thromboprophylaxis after knee and 
hip replacement orthopedic surgery, stroke prevention 
in conjunction with non-valvular atrial fibrillation 
(AF), treatment of deep venous thrombosis (DVT) or 
uncomplicated, hemodynamically stable pulmonary 
embolism (PE) (9). Uniquely for rivaroxaban, prevention 
of atherothrombotic events in coronary artery disease or 
peripheral arterial occlusive disease in conjunction with 
acetylsalicylic acid (ASA) is also recently indicated (5,10). 
Edoxaban was approved by the EMA for stroke prevention 
with AF and treatment of DVT and uncomplicated PE 
in 2015 (11). Betrixaban is not currently available in the 
European market, but is the sole DOAC with the indication 
of thromboprophylaxis for medically ill patients (12). The 
distribution of anticoagulation use is presented in Figure 2. 
Rivaroxaban is the most used DOAC in Finland at the 
moment. Recently dabigatran was found to be non-inferior 
to warfarin in the treatment of cerebral sinus venous 
thrombosis (RESPECT_CVT, submitted 2019).
Monitoring of DOAC anticoagulation effect is not 
recommended for routine use, while liver or kidney 
dysfunction, thrombosis or bleeding breakthrough during 
treatment, extremes in body weight, suspicion of non-
compliance or overdose are situations where measurement 
is useful. Routine coagulation tests such as prothrombin 
time (PT) and activated partial thromboplastin time (APTT) 
are unreliable in assessment of DOAC effect, and their 
sensitivity depends on laboratory and reagents used (13-16). 
However, the baseline assessment of PT and APTT are 
valuable screening tests to obtain an understanding of the 
Figure 1 The increasing (55%/5 years) number of consultations 
to the clinical Coagulation Disorders Unit, Department of 
Hematology and Comprehensive Cancer Centre, Helsinki 
University Hospital. The Unit was established in year 2000. The 
majority of the increased number of consultations are due to 
problems related to anticoagulation. ‘All’ consultations refer to the 
ones received to our unit, while ‘handled’ consultations refer to 
the online performed consultations, most urgent being the phone 
call consultations. The European Association of Haemophilia 
and Allied Disorders EUHANET project assigned the European 
Haemophilia Comprehensive Care Centre, EHCCC status to the 
Unit in 2014. Three to four doctors and 3–4 nurses work at the 
Unit. The Unit collaborates with the laboratory at multiple levels 
on daily basis.
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liver function prior to initiation of DOACs. Also, in case of 
severe accumulation of DOAC, both tests depict prolonged 
coagulation times. The effect and interference of DOACs 
on the other coagulation factor testing is under continuous 
discussion and education between clinic and laboratory. 
Some neutralization strategies to better interpret laboratory 
tests may be needed.
Specific assays for DOACs are available and in regular 
use nowadays (Table 1). Thrombin time (TT) is extremely 
sensitive to dabigatran and can be diluted and calibrated 
with known drug concentrations, one modification of such 
is used in our laboratory. Ecarin clotting assay (ECA) based 
methods have also proven to be accurate (14).
Chromogenic anti-FXa assay can be calibrated with 
known concentrations of FXa inhibitors (FXaI) to provide 
a functional assay for estimating concentration. However, 
all FXa-inhibiting drugs, including indirect FXa inhibitors, 
such as heparin, elicit a response. A calibrated assay is said to 
be specific for the given FXaI, and the clinician must ask for 
the specific assay compatible with the current FXaI in use 
(not just request a FXa assay). This is important as anti-FXa 
sensitivities to different FXaIs vary. As an example, edoxaban 
amounts to the strongest anti-FXa inhibition in the low 
molecular weight heparin (LMWH) calibrated assays. On the 
other hand FXaIs can be quite reliably traced and excluded 
with LMWH assay (11,17,18), which is particularly relevant 
where the specific assay is not available for 24/7.
Antidotes for DOACs have been launched with a delay. 
Idarucizumab, a monoclonal antibody against dabigatran 
without any influence on thrombin, was licensed by the 
EMA and was available in Finland in late 2015 when 
we nationally launched web-based practical guidance to 
clinicians to approach problematic emergency cases (19). 
FXaI antidote andexanet alpha, effective against all the 
FXaIs, became available in EU only recently (20). The 
pricing will be unfortunately very high, so a rapid nation-
specific health economic analysis will be needed prior 
the potential use of andexanet. Until now, the reversal of 
the FXaIs has been successfully performed with 4-factor 
prothrombin complex concentrates (PCC) (21).
DOAC reversal is indicated under acute situations, 
where it is not feasible to wait for drug elimination. These 
include drug overdose, acute kidney or liver failure, major 
bleed, trauma or urgent procedure with significant bleeding 
risk. Approximately 2–4% of patients on anticoagulation 
therapy encounter a major bleed and a further 2% require 
urgent procedure(s) while anticoagulated (22). In 2018, in 
the Helsinki and Uusimaa Hospital District, idarucizumab 
was used 120 times. More detailed analyses of these cases 
revealed that laboratory analyses (blood count, DOAC 
concentrations) were assessed only in a third of the patients, 
despite national guidelines from 2015 on DOAC on 
reversal, as idarucizumab is directly available to clinicians 
from the hospital pharmacy.
While typical DOAC concentrations during treatment 
are known, based on previous patient studies, actual 
concentrations observed in real-life patients may widely 
vary, 10- or even 100-fold at both peak and trough. Peak 
and trough levels for DOACs dabigatran, rivaroxaban and 
apixaban obtained in selected patient sample studies are 
Figure 2 The use of oral anticoagulants in Finland, data source IQVIA 12/2018. The use of warfarin is decreasing and DOACs increasing. 
DOAC purchase peak in the turn of the years 2017–2018 due to stock replenishment of the pharmacies (IQVIA Finland, The Human Data 
Science CompanyTM).
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Table 1 The commonly used anticoagulants available in Finland
Anticoagulant Indication Advantages Disadvantages
Laboratory 
measurement
Unfractionated 
heparin, UFH
Anticoagulation during surgical 
procedures, intensive care, 
resolution of hemodynamically 
unstable pulmonary embolism 
High therapeutic doses 
possible, antidote 
protamine sulfate available
Intravenous or subcutaneous 
dosing, highest risk 
of heparin-induced 
thrombocytopenia (HIT)
APTT, TT, Anti-Xa, ACT
Low-molecular 
weight heparin, 
LMWH
Anticoagulation during 
hospitalization, in active cancer, 
bridging treatment with warfarin, 
thrombophilias
Dosed subcutaneously, 
easier to use than 
unfractionated heparin, 
lower risk of HIT, antidote 
protamine sulfate available, 
although less effective 
than for UFH
Parenteral subcutaneous 
dosing
Anti-Xa
Warfarin, VKA Almost all long-term situations 
requiring anticoagulation, 
including artificial heart valve, 
thrombophilia and cancer
Long experience on clinical 
use, readily monitored 
with INR, vitamin K readily 
available as antidote, for 
urgent reversal, PCC
Regular visits to the 
laboratory required for INR 
checks 
INR
Dabigatran Non-valvular AF, treatment of PE, 
DVT
No routine laboratory 
monitoring, fixed dose
Antidote idarucizumab 
expensive and not always 
available, PCC as an 
alternative, dabigatran 
cannot be used in kidney 
failure
diluted thrombin time 
(dTT) calibrated for 
dabigatran, ecarin 
clotting assay (ECA)
Rivaroxaban Non-valvular AF, treatment 
of PE, DVT, prevention of 
atherothrombosis
No routine laboratory 
monitoring, fixed dose, 
once-daily dosing
Antidote andexanet alpha, 
expensive and not readily 
available, PCC as an 
alternative
Anti-Xa calibrated for 
rivaroxaban
Apixaban Non-valvular AF, treatment of PE, 
DVT
No routine laboratory 
monitoring, fixed dose
Antidote andexanet alpha 
expensive and not readily 
available, PCC as an 
alternative
Anti-Xa calibrated for 
apixaban
Edoxaban Non-valvular AF No routine laboratory 
monitoring, fixed dose, 
once-daily dosing
Antidote andexanet alpha 
expensive and not readily 
available, PCC as an 
alternative
Anti-Xa calibrated for 
edoxaban
ACT, activated clotting time; AF, atrial fibrillation; Anti-Xa, anti-factor Xa assay; APTT, activated partial thromboplastin time; dTT, diluted 
thrombin time; DVT, deep vein thrombosis; ECA, ecarin clotting assay; HIT, heparin-induced thrombocytopenia; INR, international 
normalized ratio; LMWH, low molecular weight heparin; PCC, prothrombin complex concentrate; PE, pulmonary embolism; TT, thrombin 
time; UFH, unfractionated heparin.
shown in Tables 2-4. In a recent study, the mean peak level 
of edoxaban was 301 ng/mL (range, 60–569 ng/mL) and 
trough level was 39 ng/mL (range, 13–110 ng/mL) in 48 AF 
patients with an edoxaban OD dose of 60 mg (37).
VKAs (warfarin)
Warfarin is the traditional oral anticoagulant with decades 
of experience for its use. The clinical indications of warfarin 
include: (I) stroke prevention in all forms of AF, including 
valvular and under mechanical valvular replacement, 
(II) treatment of DVT and PE (including complicated, 
hemodynamically unstable PE), and other rare locations of 
thrombosis (e.g., cerebral sinus and portal vein thrombosis), 
although initial heparin bridging is used when treating acute 
thrombosis, (III) secondary prevention of thrombotic events 
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Table 2 Dabigatran levels in patient sample studies varied significantly interindividually
Study Indication Dose
Number of 
patients
Peak level (ng/mL) Trough level (ng/mL) Measurement 
method
Reference
Mean Median Range Mean Median Range
Antovic et al. 
2013
Atrial fibrillation Not reported 70 <0.5–586 LC-MS/MS (23)
Reilly et al. 2014 Atrial fibrillation 110 mg BID 4,583 126 133 1–745 65 66 1–608 LC-MS/MS (24)
Reilly et al. 2014 Atrial fibrillation 150 mg BID 4,600 175 184 2–1,000 91 93 1–809 LC-MS/MS (24)
Skeppholm et al. 
2014
Atrial fibrillation 110 mg BID 17 60 23–168 LC-MS/MS (25)
Skeppholm  
et al. 2014
Atrial fibrillation 150 mg BID 73 52 8–188 LC-MS/MS (25)
Chan et al. 2015 Atrial fibrillation 110–150 mg BID 100 155 <30–722 dTT (26)
Shimomura  
et al. 2015
Atrial fibrillation 110 mg BID 259 79 dTT (27)
Shimomura  
et al. 2015
Atrial fibrillation 150 mg BID 57 128 dTT (27)
Freyburger et al. 
2011
Hip or knee 
replacement
150–220 mg OD 40 105 dTT (28)
Herrmann et al. 
2013
Hip or knee 
replacement
150 mg BID 17 129 68 dTT (29)
Samama et al. 
2013
Hip or knee 
replacement
150–220 mg OD 65 51 0–324 dTT (30)
Schellings et al. 
2016
Hip or knee 
replacement
220 mg OD 40 81 12 LC-MS/MS (31)
Testa et al. 2016 Various 110 mg BID 90 170 30–650 120 10–400 dTT (32)
Testa et al. 2016 Various 150 mg BID 70 180 30–550 120 10–500 dTT (32)
Lin et al. 2018 Various 110 mg BID 38 (33)
Lin et al. 2018 Various 150 mg BID 8 (33)
BID, twice daily; dTT, diluted thrombin time; LC-MS/MS, liquid chromatography tandem mass spectrometry. 
after myocardial infarction and (IV) prevention of DVT in 
the setting of surgery.
Warfarin has wide intra- and interindividual variation in 
its metabolism. The active S enantiomer of warfarin exhibits 
significant metabolic variation, the variants contributing 
to increased warfarin sensitivity, include CYP2C9*2 
(c.430C>T) and *3 (c.1075A>C) and VKORC1 c.-1639G>A 
variant (38,39). In addition, the amount of vitamin K in 
the diet, cigarette smoking, alcohol consumption and 
many medications interact with warfarin effect, mandating 
regular laboratory monitoring upon warfarin use (40). 
The International Normalized Ratio (INR), derived from 
PT and standardized between laboratories using the 
International Sensitivity Index (ISI), is used to monitor 
warfarin effect (41). The INR treatment target is usually 
2.0–3.0, with higher treatment target of 2.5–3.5 used 
in patients with mechanical heart valve replacement, 
corresponding to higher warfarin dose in these patients (42). 
It is noteworthy that no DOACs have been approved for 
use with the mechanical heart valves, and we are not aware 
of any such ongoing studies.
Quality of warfarin anticoagulation for patients has been 
measured according to time in therapeutic range (TTR), 
especially in research settings for over two decades. In the 
Rosendaal method of calculating TTR, the INR is assumed 
to change linearly between dates of measurement and total 
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Table 3 Rivaroxaban levels in patient sample studies
Study Indication Dose
Number of 
patients
Peak level (ng/mL) Trough level (ng/mL) Measurement 
method
Reference
Mean Median Range Mean Median Range
Freyburger  
et al. 2011
Hip or knee 
replacement
10 mg OD 40 117 Anti-Xa (28)
Herrmann  
et al. 2013
Hip or knee 
replacement
10 mg OD 15 133 5 Anti-Xa (29)
Freyburger  
et al. 2015
Hip or knee 
replacement
10 mg OD 51 113 7 LC-MS/MS (34)
Samama  
et al. 2013
Hip or knee 
replacement
10 mg OD 41 142 0–412 Anti-Xa (30)
Schellings  
et al. 2016
Hip or knee 
replacement
10 mg OD 40 125 17 LC-MS/MS (31)
Arachillage  
et al. 2016
Thromboembolism 20 mg OD 105 280 Anti-Xa (35)
Testa et al. 
2016
Various 20 mg OD 37 210 50–450 30 5–140 Anti-Xa (32)
Testa et al. 
2016
Various 15 mg OD 34 180 60–410 20 5–120 Anti-Xa (32)
Suwa et al. 
2019
Atrial fibrillation 15 mg OD 90 348 150–610 28 0–100 Anti-Xa (36)
Suwa et al. 
2019
Atrial fibrillation 10 mg OD 46 270 120–480 26 0–120 Anti-Xa (36)
LC-MS/MS, liquid chromatography tandem mass spectrometry; OD, once daily.
Table 4 Apixaban levels in patient sample studies
Study Indication Dose
Number of 
patients
Peak level (ng/mL) Trough level (ng/mL) Measurement 
method
Reference
Mean Median Range Mean Median Range
Freyburger  
et al. 2015
Hip or knee 
replacement
2.5 mg BID 51 76 45 LC-MS/MS (34)
Testa et al. 2016 Various 5 mg BID 73 200 110–440 140 30–400 Anti-Xa (32)
Testa et al. 2016 Various 2.5 mg BID 26 160 50–300 100 20–280 Anti-Xa (32)
Suwa et al. 2019 Atrial fibrillation 5 mg BID 58 237 100–550 108 30–190 Anti-Xa (36)
Suwa et al. 2019 Atrial fibrillation 2.5 mg BID 61 157 60–480 68 10–170 Anti-Xa (36)
BID, twice daily; dTT, diluted thrombin time; LC-MS/MS, liquid chromatography tandem mass spectrometry.
number of days in the therapeutic range is then calculated as 
a percentage (43). TTR can be used to assess the quality of 
therapy at individual patient level or at treatment center’s—
typical TTRs in warfarin patients range from 55–60% in 
USA and central Europe to over 70% in Sweden (44-48). 
TTR should only be used for long-term warfarin treatment 
when the patient is in a clinically stable condition, without 
interruptions in warfarin treatment. During acute illness 
or trauma, hospitalization with warfarin interruptions and 
heparin use, TTR is decreased, but this offers very limited 
information on warfarin suitability to a given patient. We 
offer a TTR calculator freely available on the Internet, 
Annals of Blood, 2019 Page 7 of 14
© Annals of Blood. All rights reserved. Ann Blood 2019;4:17 | http://dx.doi.org/10.21037/aob.2019.07.01
including guidance in its rational use. Patients benefit from 
well-performing centers overall, centers with higher TTR 
during warfarin fare better with DOAC anticoagulation 
as well (49). While transitioning from warfarin to 
DOACs, the challenge is maintaining the high quality and 
adequate frequency of clinical follow-ups, when laboratory 
monitoring is no longer necessary (i.e., when on DOACs).
INR self-testing and self-management of warfarin 
are suitable options for motivated patients; even in the 
era of DOACs there is a special need. Not surprisingly, 
TTR values are best in patients participating in the self-
management programs (50). When of high quality, self-
testing performs well and is reliable, safe and efficient, 
increases patient safety and satisfaction, and decreases 
complications and even mortality (51,52). Professional 
training for patient selection is crucial, as appropriate skills 
and the ability to commit to the program are needed. We 
have offered a patient self-monitoring service since 2015. 
The program includes patient selection and training by the 
anticoagulation nurse and a laboratory technician, so that 
the patient acquires competency in both warfarin dosing 
and point-of-care (POC) INR measurement. The demand 
to serve new patients is currently higher than our capacity, 
and some primary healthcare units are being trained for 
this purpose as well. At the moment, the remuneration of 
self-management (devices, test strips and lancets) varies 
according to the different municipalities, which limits the 
adoption of the model nationwide.
Heparins
Heparins are of animal origin, from porcine and bovine 
gut mucosa, that is another reason why the synthetic 
anticoagulants appear important in the anticoagulation 
armamentarium. The unfractionated heparins (UFH) with 
chains of 10–20 kDa in molecular weight are administered 
in cardiac and vascular surgery setting and during 
plasma exchange. Therein contact activation demands an 
anticoagulant acting both at the level of thrombin and other 
coagulation factors. The development and subcutaneous 
administration of LMWH was a major milestone in the 
1970s.
The strengths of heparin include its subcutaneous (sc) 
administration route, when oral route is not reliable; its anti-
inflammatory actions and relatively short half-life, 90 min 
for UFH and 4–6 hours for LMWH depending on the 
dosing (53). Dabigatran and edoxaban when used to manage 
venous thromboembolism, requires use of LMWH first 
for a few days, prior to their initiation. LMWH is the 
drug of choice for cancer patients at vulnerable phases 
of chemotherapies and surgery, including pathological 
fractures (54). Also, pediatric and pregnant patients 
continue to benefit from this safe strategy to manage and 
prevent thrombosis. For hospitalized medically ill patients, 
LMWH as a thromboprophylactic therapy has the most 
solid evidence of balanced safety and efficacy, while DOACs 
failed in this indication, with the exception of betrixaban. 
Also, high risk warfarin treated patients having cardiac 
valvular replacement need LMWH bridging. The limitation 
of heparin is its immunological side effects, including 
heparin-induced thrombocytopenia, with even paradoxical 
thrombosis. The smallest effective unit of heparin is 
pentasaccharide, fondaparinux, which binds to antithrombin 
and as a synthetic mode of parenteral FXa inhibition offers 
an option to some heparin-intolerant patients.
In specific indications, LMWH and fondaparinux can 
be measured with the chromogenic anti-FXa assay. Like 
the FXaIs mentioned previously, the assay requires specific 
calibration. The aim of the monitoring of these drug effects 
is to acquire high enough dosing in thrombophilic patients 
and vice versa, in vulnerable organ-function compromised 
patients to avoid bleeding complications.
Summary of the anticoagulation options with their 
advantages and disadvantages are given in Table 1.
Clinical use of oral anticoagulation and 
laboratory testing in different clinical situations
Oral anticoagulation in cardiology
In heart disease, the most common indications for 
anticoagulation are AF, mechanical heart valve replacement 
and severe mitral stenosis. A DOAC is the drug of choice 
in most new patients, except for those with a mechanical 
heart valve, moderate to severe mitral stenosis or advanced 
renal failure (55). Individual risk assessment for stroke 
(CHA2DS2VASc) and bleeding (HAS-BLED) are guiding 
the choice of anticoagulation. Yet, there are problems 
with these scores. At a broad level, some of the scores 
are semiquantitative, and more attention is needed for a 
comprehensive understanding of the individual patient’s 
coagulation status. It is important to assess patient history 
on a prolonged time period, as limiting attention to only 
past six months has been shown to lead to underestimation 
of risk in CHA2DS2VASc score (56). Iron deficiency 
anemia is often overlooked, while it is a correctable risk 
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factor for bleeds. Hypertension predisposes to intracerebral 
hemorrhage, as well as other bleeds, and is commonly 
present in cardiac patients.
Clinical scoring systems account for patient age, 
frailty, renal and liver dysfunction to varying degrees, 
while all significantly affect DOAC response. In acute 
coronary syndrome, dual antithrombotic therapy seems 
to be as effective as triple antithrombotic therapy, but is 
not surprisingly associated with significantly lower major 
bleeding risk (57). Anticoagulants may also be used in 
cerebrovascular disorders unrelated to AF (e.g., in cerebral 
venous thrombosis, basilar artery occlusion, or carotid or 
vertebral artery dissection). However, evidence on the use 
of DOACs in these special circumstances is still relatively 
weak. Critical studies are underway (58), and first line 
drugs are LMWH and warfarin. Use of DOACs is likely to 
increase along with new evidence as it is gained.
Oral anticoagulation and renal impairment
The incidence of chronic renal disease is increasing along 
with the aging population. For many clinical situations, 
knowledge on safety and efficacy of medications is lacking. 
Renal insufficiency exposes the risk of both bleeding and 
thrombosis complications, and while anticoagulation 
appears indicated, it is simultaneously challenging. Risk 
assessment tools with CHA2DS2VASc and HAS-BLED are 
not validated in these patients, while renal impairment is a 
relevant concern in cardiac patients (57). Clinical decisions 
on anticoagulation should be individualized with the help 
of laboratory testing. In case of mild and moderate renal 
insufficiency, with glomerular filtration rate (GFR) less than 
30 mL/min, the dose of DOAC must be lowered. Patients 
on anticoagulation should be followed regularly, and more 
frequently when renal function declines, as the safety, the 
choice of management (need of dialysis), the drug and the 
dose of anticoagulation therapy should be re-evaluated.
Dabigatran is 80% excreted by kidneys, and it is 
cumulating to extravascular tissues during renal dysfunction. 
If GFR is <30 mL/min, dabigatran is contraindicated. If 
GFR is 30–50 mL/min, a lower dose of 110 mg BID must 
be chosen. However, renal extraction is lower for FXaIs, 
for apixaban, 27%, rivaroxaban 50% and edoxaban 35%. 
In renal impairment, apixaban is currently preferred, with 
the lower dose of 2.5 mg BID recommended in case of 
creatinine >133 mmol/L, elderly patients (>80 yrs) and small 
weight (<60 kg) (59). Finally, renal patients are subjected to 
the most severe complications of drug interactions, which 
tend to be increasingly identified (8).
Oral anticoagulation and surgery or invasive procedures 
and trauma
The management of chronic anticoagulation therapy 
in patients undergoing surgical procedures or trauma 
needs careful planning. Surgery, invasive procedures 
and trauma all have associated bleeding risks that 
are increased by the anticoagulant administered for 
prevention of thromboembolism. At the same time, 
interrupting anticoagulation transiently increases the risk 
of thromboembolism at least due to surgery-triggered 
exposure of vascular collagen and tissue factor. Warfarin 
therapy may be continued if the bleeding risk is manageable. 
However, warfarin should be stopped during high bleeding 
risk procedures and the physicians should carefully 
consider the need for bridging with LMWH with either 
full or prophylactic dose. According to the latest findings, 
bridging anticoagulation may be of no benefit in preventing 
thromboembolism and may increase the incidence of 
bleeding in patients with moderate thrombotic risk. In the 
Bridge study, forgoing heparin bridging anticoagulation 
in AF patients was non-inferior to perioperative LMWH 
bridging (60). However, patients included were low risk 
and bridging is recommended in patients with mechanical 
heart valve or other high risk for thromboembolism (61). 
Thus, for patients with high thromboembolic risk, bridging 
with LMWHs remains a valid strategy. The use of DOACs, 
during perioperative situations, is increasing in clinical 
practice, although without evidence.
Acute bleeding complication and oral anticoagulation
During major bleeds, anticoagulation should be either 
stopped and/or reversed, depending on the severity 
and localization of the bleed and the half-life of the 
anticoagulant. The timing of the last intake of the 
anticoagulant is relevant information, especially in the 
case of DOACs. Warfarin may be reversed with vitamin 
K and PCC, dabigatran by idarucizumab, and FXaIs with 
andexanet alpha (19-21); however, a clearly limiting factor 
is that specific antidotes are available in the major hospitals 
only. PCC can be used if antidote is not available or cost 
constraints preclude its use. Supportive care includes single 
dose of iv tranexamic acid and replacement of appropriate 
blood products according to laboratory analysis. Regardless 
of the severity of bleeding, other risk factors should be 
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treated, i.e., anemia, thrombocytopenia, and hypertension. 
Possible renal or liver dysfunction must also be assessed, 
since impairment of hemostasis and drug accumulation 
potentiates the worsening of hemostasis during acute bleed.
Oral anticoagulation and thrombophilia
Currently for patients with hereditary thrombophilia, 
DOACs are not usually the primary anticoagulant 
recommended under these conditions (9-11,59). In the RE-
MEDY trial, small subgroup analysis, dabigatran seemed 
noninferior to warfarin in thrombophilia patients (protein 
C or S deficiency, antithrombin deficiency, antiphospholipid 
antibodies, FV Leiden or prothrombin variant heterozygous 
mutation) (62). Rivaroxaban was assessed as noninferior 
to warfarin in phospholipid antibody syndrome (APS) in a 
phase III trial (63); however, the most severe APS patients 
did not benefit from rivaroxaban in comparison with 
warfarin (64). Overall, the evidence for use of DOACs in 
these rare conditions remains limited, with much of the 
data still based on case reports (65). For the time being, 
the EMA is evaluating APS data of DOAC treatments, and 
warfarin and heparin remain the mainstay.
Oral anticoagulation and laboratory testing 
While anticoagulation therapy has changed dramatically, 
one of the major alterations is also the change in laboratory 
practice. Although the number of DOAC users is steadily 
increasing, the remuneration policies in each country are 
the main limiting factor for more widespread use. Since 
2–3% of the population is now using anticoagulation 
therapy, the impact on the laboratory is remarkable (66). 
Clinicians in the Northern countries are increasingly 
preferring DOACs over warfarin. However, when DOACs 
were launched a decade ago, one of the main requirements 
and concerns were how to measure the effect and level of 
anticoagulation (13). Clinicians were initially hesitant to 
start such a drug, the effect of which could not be assessed.
Quite quickly, we learned that routine coagulation tests 
PT and APTT were of little use in case of DOACs (13). 
There are large variations in sensitivity of different 
methods and reagents used. Owren type PT/INR, as used 
in the Nordic countries, is insensitive to DOACs and FV 
deficiency (impaired liver function), and this is still a matter 
of education for our clinicians (16). APTT may show an 
effect of dabigatran, whereas FXaIs affect the APTT less, or 
do not affect the APTT (15,16,67-69). More specific assays 
were quickly needed, and HUSLAB laboratory services was 
the first laboratory in Finland to set up the specific assays for 
dabigatran, rivaroxaban and apixaban, and offer them 24/7 
for clinical use (since May 2017). The number of requested 
tests is still small, but increasing, the growth being fastest 
for apixaban, which came to the market later but is rapidly 
catching up (Figure 3). At the same time, number of INR 
tests has steadily declined annually by 10–15% since 2015. 
Yet, we also note that other coagulation testing, i.e., PT, 
APTT, fibrinogen, is increasing. In Finland, laboratory 
personnel, trained laboratory technicians, perform 
phlebotomy and take almost all the blood samples. The 
changes in coagulation test ordering practices widely impact 
on requirements of out-patient clinic blood sampling design 
also in the future.
Anticoagulation treatment increases the risk of bleeding 
complications, especially in the elderly, patients with cancer 
or with renal and liver dysfunction. To minimize the risk 
of bleeding, all anticoagulated patients should have regular 
follow-ups at minimum once, but in case of co-morbidities 
more frequently, at least 2–4 times annually (8,55). 
Laboratory testing during such visits may help to 
assess the thrombotic burden, i.e., thrombophilia panel, 
high fibrinogen and FVIII, and elevated D-dimer (70-72) 
(Figure 4). Thrombotic and bleeding tendencies and 
complicat ions,  adverse effects ,  adherence,  blood 
pressure, renal and liver function, comorbidities and drug 
interactions, possible anemia and thrombocytopenia, as well 
Figure 3 The availability and use of DOAC laboratory tests at 
Helsinki and Uusimaa in 2011–2018. Apixaban is experiencing the 
fastest growth, although entering the market later than rivaroxaban 
or dabigatran. Apix, apixaban; Riva, rivaroxaban; Dabi, dabigatran.
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as the appropriateness (dose and product) of the current 
anticoagulation should be repeatedly addressed during 
regular follow-ups. This assessment should be repeated at 
each patient clinical visit.
Specific, calibrated anticoagulant measurement tests 
are needed in special clinical situations to capture the 
extent of anticoagulation, in terms of timing of the drug 
dosing and blood sampling. The effective levels vary 
widely, with overlapping peaks and troughs at a steady 
state. Under special complications, it is advisable to 
assess whether the level is on-or off-therapy range. The 
level of anticoagulation should be optimized where there 
is potential for over-anticoagulation: acute bleeding, 
preoperatively overdosing, renal failure, low BMI, acute 
medical illness, drug interactions and in the elderly patients, 
and in cases of under-anticoagulation: treatment failure, 
obesity, malabsorption and drug interactions (73,74).
In case of trauma, acute procedure and need of antidote, 
the test is requested to save time and help decision-making 
at critical moments (Figure 4). For many laboratories, it is 
difficult to keep up 24/7 services for few requests and the 
distances to the nearest laboratory will increase compared 
with standard INR availability. While point-of-care INR 
and activated clotting time (ACT) have some sensitivity to 
rivaroxaban, the authors opine that POC testing of DOACs 
is unlikely to offer solutions for the near future (75-78), 
although POC tests specifically targeted to DOACs are 
emerging (79,80). It is also noteworthy, that national and 
local conditions will dictate the access to (e.g., special) 
assays to measure DOAC effects, depending on the part of 
the Hospital District the patients reside in.
Novel global approaches for anticoagulation management 
feasibly include viscoelastic testing and thrombin 
generation. Viscoelastic tests, the TEG® and ROTEM® 
are well suited for acute assessment of fibrin deficiency 
and massive bleeding complications in the emergency 
rooms or operating theaters. For both warfarin and 
DOACs, viscoelastic assays have shown conflicting data on 
detecting anticoagulation, and they are not recommended 
for monitoring (81,82). Thrombin generation assays have 
the potential to detect any anticoagulant, but their use is 
currently still limited to the research laboratory (83). Novel 
standardized methods, including the Stago ST Genesia® 
will probably become clinical routine in the near future (84).
Conclusions
In the future of anticoagulation therapy, individual decisions 
and practices will be even more common. Basic laboratory 
testing, including blood cell counts with hematocrit, 
hemoglobin, leukocyte and platelet count, creatinine and 
estimated GFR and liver enzymes (ALT) as well as function 
tests (prealbumin, albumin, PT, lipids) and basic metabolic 
assays (pH, electrolytes and cations) are crucial in the risk 
assessment, but will also increasingly become a part of the 
regular follow-up of anticoagulated patients. The number 
of INR tests continues to decrease, as the usage of warfarin 
declines. DOACs will mainly replace warfarin, imposing 
additional requirements for specific testing under acute 
clinical situations, such as major bleeds, thrombosis and 
emergency surgery or trauma. Pediatric and pregnant 
populations as well as cancer patients will require the 
gathering of more evidence as to how to most optimally 
secure their anticoagulation management.
Figure 4 Grey zone of coagulation activity. The modern management of coagulation disorders, the subcutaneous non-factor therapies for 
haemophilia (emicizumab, fitusiran and concizumab) and DOACs, is initially assigned not to be monitored at all. Measurement of the status 
of the coagulation system, however, is important during trauma, bleeding episodes, breakthrough bleeds or thrombosis while on treatment 
and emergency surgery. 
pH
Calcium
Magnesium
RBC, platelets, leuk
PT/APTT/TT screen
fibrinogen, ADAMTS13 
VWF/FVIII/FIX
FXIII… CRP = C-reactive protein
Lipid profile
Complement system
Insulin resistance
Endothelium: NO, Prostacyclin, ectoADPase
Natural anticoagulants: AT, PC (thrombomodulin), PS, TFPI
Fibrinolysis and its regulation: plasminogen, antiplasmin, D-dimer
Bleeder Clotter
Annals of Blood, 2019 Page 11 of 14
© Annals of Blood. All rights reserved. Ann Blood 2019;4:17 | http://dx.doi.org/10.21037/aob.2019.07.01
Acknowledgments
None.
Footnote
Conflicts of Interest: The authors have no conflicts of interest 
to declare.
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. 
References
1. Salmela B, Joutsi-Korhonen L, Armstrong E, et al. 
Active online assessment of patients using new oral 
anticoagulants: bleeding risk, compliance, and coagulation 
analysis. Semin Thromb Hemost 2012;38:23-30. 
2. Lassila R, Armstrong E, Halinen M, et al. Uusien 
antikoagulanttien hallittu käyttöönotto. Suom Lääkäril 
2011;66:2753-62.
3. Helin TA, Lemponen M, Hjemdahl P, et al. From 
laboratory to clinical practice: Dabigatran effects on 
thrombin generation and coagulation in patient samples. 
Thromb Res 2015;136:154-60. 
4. Helin TA, Virtanen L, Manninen M, et al. Effects of 
thromboprophylactic doses of apixaban and rivaroxaban 
on coagulation and thrombin generation in association 
with total hip replacement. J Thromb Thrombolysis 
2017;43:562-9. 
5. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban 
with or without aspirin in patients with stable peripheral 
or carotid artery disease: an international, randomised, 
double-blind, placebo-controlled trial. Lancet 
2018;391:219-29. 
6. Laube ES, Yu A, Gupta D, et al. Rivaroxaban for Stroke 
Prevention in Patients With Nonvalvular Atrial Fibrillation 
and Active Cancer. Am J Cardiol 2017;120:213-7. 
7. Melloni C, Dunning A, Granger CB, et al. Efficacy and 
Safety of Apixaban Versus Warfarin in Patients with Atrial 
Fibrillation and a History of Cancer: Insights from the 
ARISTOTLE Trial. Am J Med 2017;130:1440-1448.e1. 
8. Heidbuchel H, Berti D, Campos M, et al. Implementation 
of non-vitamin K antagonist oral anticoagulants in daily 
practice: the need for comprehensive education for 
professionals and patients. Thromb J 2015;13:22.
9. EMA. EPAR Summary for the public: Pradaxa. 
EMA/54606/2012. Available online: https://www.ema.
europa.eu/en/medicines/human/EPAR/pradaxa#product-
information-section
10. EMA. Xarelto Summary of Product Characteristics. 
EMEA/H/C/000944 -IB/0040/G 2009. Available online: 
https://www.ema.europa.eu/en/medicines/human/EPAR/
xarelto#product-information-section
11. EMA. EPAR Summary for the Public Lixiana. EMEA/
H/C/002629 2017. Available online: https://www.ema.
europa.eu/en/medicines/human/EPAR/lixiana#product-
information-section
12. Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended 
Thromboprophylaxis with Betrixaban in Acutely Ill 
Medical Patients. N Engl J Med 2016;375:534-44. 
13. Baglin T, Hillarp A, Tripodi A, et al. Measuring Oral 
Direct Inhibitors (ODIs) of thrombin and factor Xa: A 
recommendation from the Subcommittee on Control 
of Anticoagulation of the Scientific and Standardisation 
Committee of the International Society on Thrombosis 
and Haemostasis. J Thromb Haemost 2013. [Epub ahead 
of print].
14. Favaloro EJ, Pasalic L, Curnow J, et al. Laboratory 
Monitoring or Measurement of Direct Oral Anticoagulants 
(DOACs): Advantages, Limitations and Future Challenges. 
Curr Drug Metab 2017;18:598-608. 
15. Hillarp A, Strandberg K, Baghaei F, et al. Effects of 
the oral, direct factor Xa inhibitor edoxaban on routine 
coagulation assays, lupus anticoagulant and anti-Xa assays. 
Scand J Clin Lab Invest 2018;78:575-83. 
16. Helin TA, Pakkanen A, Lassila R, et al. Laboratory 
assessment of novel oral anticoagulants: method suitability 
and variability between coagulation laboratories. Clin 
Chem 2013;59:807-14. 
17. He L, Kochan J, Lin M, et al. Determination of edoxaban 
equivalent concentrations in human plasma by an 
automated anti-factor Xa chromogenic assay. Thromb Res 
2017;155:121-7. 
18. Becker RC, Yang H, Barrett Y, et al. Chromogenic 
laboratory assays to measure the factor Xa-inhibiting 
properties of apixaban--an oral, direct and selective factor 
Xa inhibitor. J Thromb Thrombolysis 2011;32:183-7. 
19. Pollack CV,Jr, Reilly PA, Eikelboom J, et al. Idarucizumab 
for Dabigatran Reversal. N Engl J Med 2015;373:511-20. 
20. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet 
Alfa for the Reversal of Factor Xa Inhibitor Activity. N 
Engl J Med 2015;373:2413-24. 
21. Samuelson BT, Cuker A. Measurement and reversal of the 
Annals of Blood, 2019Page 12 of 14
© Annals of Blood. All rights reserved. Ann Blood 2019;4:17 | http://dx.doi.org/10.21037/aob.2019.07.01
direct oral anticoagulants. Blood Rev 2017;31:77-84. 
22. Tornkvist M, Smith JG, Labaf A. Current evidence of oral 
anticoagulant reversal: A systematic review. Thromb Res 
2018;162:22-31. 
23. Antovic JP, Skeppholm M, Eintrei J, et al. Evaluation of 
coagulation assays versus LC-MS/MS for determinations 
of dabigatran concentrations in plasma. Eur J Clin 
Pharmacol 2013;69:1875-81. 
24. Reilly PA, Lehr T, Haertter S, et al. The effect 
of dabigatran plasma concentrations and patient 
characteristics on the frequency of ischemic stroke 
and major bleeding in atrial fibrillation patients: 
the RE-LY Trial (Randomized Evaluation of Long-
Term Anticoagulation Therapy). J Am Coll Cardiol 
2014;63:321-8. 
25. Skeppholm M, Hjemdahl P, Antovic JP, et al. On the 
monitoring of dabigatran treatment in "real life" patients 
with atrial fibrillation. Thromb Res 2014;134:783-9. 
26. Chan NC, Coppens M, Hirsh J, et al. Real-world 
variability in dabigatran levels in patients with atrial 
fibrillation. J Thromb Haemost 2015;13:353-9. 
27. Shimomura D, Nakagawa Y, Kondo H, et al. Relationship 
between plasma dabigatran concentration and activated 
partial thromboplastin time in Japanese patients with non-
valvular atrial fibrillation. J Arrhythm 2015;31:183-8. 
28. Freyburger G, Macouillard G, Labrouche S, et al. 
Coagulation parameters in patients receiving dabigatran 
etexilate or rivaroxaban: two observational studies in 
patients undergoing total hip or total knee replacement. 
Thromb Res 2011;127:457-65. 
29. Herrmann R, Thom J, Wood A, et al. Thrombin 
generation using the calibrated automated thrombinoscope 
to assess reversibility of dabigatran and rivaroxaban. 
Thromb Haemost 2014;111:989-95. 
30. Samama MM, Guinet C, Le Flem L, et al. Measurement 
of dabigatran and rivaroxaban in primary prevention 
of venous thromboembolism in 106 patients, who have 
undergone major orthopedic surgery: an observational 
study. J Thromb Thrombolysis 2013;35:140-6. 
31. Schellings MW, Boonen K, Schmitz EM, et al. 
Determination of dabigatran and rivaroxaban by 
ultra-performance liquid chromatography-tandem 
mass spectrometry and coagulation assays after major 
orthopaedic surgery. Thromb Res 2016;139:128-34. 
32. Testa S, Tripodi A, Legnani C, et al. Plasma levels of 
direct oral anticoagulants in real life patients with atrial 
fibrillation: Results observed in four anticoagulation 
clinics. Thromb Res 2016;137:178-83. 
33. Lin SY, Tang SC, Kuo CH et al. Factors affecting serum 
concentration of dabigatran in Asian patients with 
non-valvular atrial fibrillation. J Formos Med Assoc 
2019;118:1154-60
34. Freyburger G, Macouillard G, Khennoufa K, et al. 
Rivaroxaban and apixaban in orthopaedics: is there a 
difference in their plasma concentrations and anticoagulant 
effects? Blood Coagul Fibrinolysis 2015;26:925-33. 
35. Arachchillage DR, Mackie IJ, Efthymiou M, et al. 
Rivaroxaban limits complement activation compared 
with warfarin in antiphospholipid syndrome patients 
with venous thromboembolism. J Thromb Haemost 
2016;14:2177-86. 
36. Suwa M, Morii I, Kino M. Rivaroxaban or Apixaban for 
Non-Valvular Atrial Fibrillation- Efficacy and Safety 
of Off-Label Under-Dosing According to Plasma 
Concentration. Circ J 2019;83:991-9. 
37. Testa S, Dellanoce C, Paoletti C et al. Edoxaban plasma 
levels with non-valvular atrial fibrillation: Inter and 
intra-individual variability, correlation with coagulation 
screening test and renal function. Thromb Res 
2019;175:61-7 
38. Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism 
and warfarin dose requirements. Br J Clin Pharmacol 
2002;53:408-9. 
39. Owen RP, Gong L, Sagreiya H, et al. VKORC1 
pharmacogenomics summary. Pharmacogenet Genomics 
2010;20:642-4. 
40. Holbrook A, Schulman S, Witt DM, et al. Evidence-Based 
Management of Anticoagulant Therapy: Antithrombotic 
Therapy and Prevention of Thrombosis, 9th ed: American 
College of Chest Physicians Evidence-Based Clinical 
Practice Guidelines. Chest 2012;141:e152S-84S.
41. van den Besselaar AM. Standardization of the prothrombin 
time in oral anticoagulant control. Haemostasis 
1985;15:271-7. 
42. Helin TA, Joutsi-Korhonen L, Asmundela H, et al. 
Warfarin dose requirement in patients having severe 
thrombosis or thrombophilia. Br J Clin Pharmacol 
2019;85:1684-91. 
43. Rosendaal FR, Cannegieter SC, van der Meer FJ, et 
al. A method to determine the optimal intensity of oral 
anticoagulant therapy. Thromb Haemost 1993;69:236-9. 
44. Kaatz S. Determinants and measures of quality in 
oral anticoagulation therapy. J Thromb Thrombolysis 
2008;25:61-6. 
45. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and 
safety of dabigatran compared with warfarin at different 
Annals of Blood, 2019 Page 13 of 14
© Annals of Blood. All rights reserved. Ann Blood 2019;4:17 | http://dx.doi.org/10.21037/aob.2019.07.01
levels of international normalised ratio control for stroke 
prevention in atrial fibrillation: an analysis of the RE-LY 
trial. Lancet 2010;376:975-83. 
46. Lehto M, Niiranen J, Korhonen P, et al. Quality of 
warfarin therapy and risk of stroke, bleeding, and mortality 
among patients with atrial fibrillation: results from the 
nationwide FinWAF Registry. Pharmacoepidemiol Drug 
Saf 2017;26:657-65. 
47. Raatikainen MJP, Penttila T, Korhonen P, et al. The 
quality of warfarin therapy and CHA2DS2-VASc score 
associate with the incidence of myocardial infarction and 
cardiovascular outcome in patients with atrial fibrillation: 
data from the nationwide FinWAF Registry. Eur Heart J 
Cardiovasc Pharmacother 2018;4:211-9. 
48. Penttilä T, Lehto M, Niiranen J, et al. Differences in the 
risk of stroke, bleeding events, and mortality between 
female and male patients with atrial fibrillation during 
warfarin therapy. Eur Heart J Cardiovasc Pharmacother 
2019;5:29-36. 
49. Wallentin L, Lopes RD, Hanna M, et al. Efficacy and 
safety of apixaban compared with warfarin at different 
levels of predicted international normalized ratio control 
for stroke prevention in atrial fibrillation. Circulation 
2013;127:2166-76. 
50. Heneghan C, Ward A, Perera R, et al. Self-monitoring of 
oral anticoagulation: systematic review and meta-analysis 
of individual patient data. Lancet 2012;379:322-34. 
51. Regier DA, Sunderji R, Lynd LD, et al. Cost-effectiveness 
of self-managed versus physician-managed oral 
anticoagulation therapy. CMAJ 2006;174:1847-52. 
52. Heneghan CJ, Garcia-Alamino J, Spencer EA, et al. Self-
monitoring and self-management of oral anticoagulation. 
C ochrane Database Syst Rev 2016;7:CD003839. 
53. Garcia DA, Baglin TP, Weitz JIFCCP, et al. Parenteral 
Anticoagulants: Antithrombotic Therapy and Prevention 
of Thrombosis, 9th ed: American College of Chest 
Physicians Evidence-Based Clinical Practice Guidelines. 
Chest 2012;141:e24S-43S.
54. Ratasvuori M, Lassila R, Laitinen M. Venous 
thromboembolism after surgical treatment of non-spinal 
skeletal metastases - An underdiagnosed complication. 
Thromb Res 2016;141:124-8. 
55. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC 
Guidelines for the management of atrial fibrillation 
developed in collaboration with EACTS: The Task Force 
for the management of atrial fibrillation of the European 
Society of Cardiology (ESC)Developed with the special 
contribution of the European Heart Rhythm Association 
(EHRA) of the ESCEndorsed by the European 
Stroke Organisation (ESO). Eur J Cardiothorac Surg 
2016;50:e1-88.
56. Friberg L. Short lookback periods causing exaggerated 
stroke risk estimates in atrial fibrillation may expose 
patients to unnecessary anticoagulant treatment. 
Pharmacoepidemiol Drug Saf 2019. [Epub ahead of print]. 
57. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines 
for the management of acute coronary syndromes in 
patients presenting without persistent ST-segment 
elevation: Task Force for the Management of Acute 
Coronary Syndromes in Patients Presenting without 
Persistent ST-Segment Elevation of the European Society 
of Cardiology (ESC). Eur Heart J 2016;37:267-315. 
58. Covut F, Kewan T, Perez O, et al. Apixaban and 
rivaroxaban in patients with cerebral venous thrombosis. 
Thromb Res 2019;173:77-78. 
59. EMA. Eliquis Summary of Product Characteristics. 
EMEA/H/C/002148 -R/0034 2011. Available online: 
https://www.ema.europa.eu/en/medicines/human/EPAR/
eliquis#product-information-section
60. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative 
Bridging Anticoagulation in Patients with Atrial 
Fibrillation. N Engl J Med 2015;373:823-33. 
61. Pengo V, Denas G. Optimizing quality care for the oral 
vitamin K antagonists (VKAs). Hematology Am Soc 
Hematol Educ Program 2018;2018:332-8. 
62. Goldhaber SZ, Eriksson H, Kakkar A, et al. Efficacy of 
dabigatran versus warfarin in patients with acute venous 
thromboembolism in the presence of thrombophilia: 
Findings from RE-COVER(R), RE-COVER II, and RE-
MEDY. Vasc Med 2016;21:506-14. 
63. Cohen H, Dore CJ, Clawson S, et al. Rivaroxaban 
in antiphospholipid syndrome (RAPS) protocol: a 
prospective, randomized controlled phase II/III clinical 
trial of rivaroxaban versus warfarin in patients with 
thrombotic antiphospholipid syndrome, with or without 
SLE. Lupus 2015;24:1087-94. 
64. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban 
vs warfarin in high-risk patients with antiphospholipid 
syndrome. Blood 2018;132:1365-71. 
65. Skelley JW, White CW, Thomason AR. The use of direct 
oral anticoagulants in inherited thrombophilia. J Thromb 
Thrombolysis 2017;43:24-30. 
66. Finnish Medical Authority. Drug consumption statistics. 2018. 
Available online: https://www.fimea.fi/en/web/en/databases_
and_registeries/consumption
67. Helin TA, Pakkanen A, Lassila R, et al. Effects of apixaban 
Annals of Blood, 2019Page 14 of 14
© Annals of Blood. All rights reserved. Ann Blood 2019;4:17 | http://dx.doi.org/10.21037/aob.2019.07.01
on prothrombin time, activated partial thromboplastin 
time and anti-Xa assays: a European survey. Clin Chem 
Lab Med 2017;55:e178-80. 
68. Hillarp A, Gustafsson KM, Faxalv L, et al. Effects of 
the oral, direct factor Xa inhibitor apixaban on routine 
coagulation assays and anti-FXa assays. J Thromb 
Haemost 2014;12:1545-53. 
69. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the 
oral, direct thrombin inhibitor dabigatran on five common 
coagulation assays. Thromb Haemost 2011;105:371-8. 
70. Connors JM. Thrombophilia Testing and Venous 
Thrombosis. N Engl J Med 2017;377:1177-87. 
71. Jenkins PV, Rawley O, Smith OP, et al. Elevated factor 
VIII levels and risk of venous thrombosis. Br J Haematol 
2012;157:653-63. 
72. Bjøri E, Johnsen HS, Hansen JB, et al. D-dimer at venous 
thrombosis diagnosis is associated with risk of recurrence. 
J Thromb Haemost 2017;15:917-24. 
73. Piran S, Traquair H, Chan N, et al. Peak plasma 
concentration of direct oral anticoagulants in obese 
patients weighing over 120 kilograms: A retrospective 
study. Res Pract Thromb Haemost 2018;2:684-8. 
74. Molteni M, Crippa M, Orenti A, et al. Investigation on 
Dabigatran Etexilate and Worsening of Renal Function 
in Patients with Atrial fibrillation: The IDEA Study. Clin 
Drug Investig 2019;39:355-62. 
75. van Ryn J, Baruch L, Clemens A. Interpretation of point-
of-care INR results in patients treated with dabigatran. Am 
J Med 2012;125:417-20. 
76. Mani H, Herth N, Kasper A, et al. Point-of-care 
coagulation testing for assessment of the pharmacodynamic 
anticoagulant effect of direct oral anticoagulant. Ther 
Drug Monit 2014;36:624-31. 
77. Ebner M, Birschmann I, Peter A, et al. Point-of-care 
testing for emergency assessment of coagulation in 
patients treated with direct oral anticoagulants. Crit Care 
2017;21:32.
78. Ebner M, Peter A, Spencer C, et al. Point-of-Care Testing 
of Coagulation in Patients Treated With Non-Vitamin K 
Antagonist Oral Anticoagulants. Stroke 2015;46:2741-7. 
79. Ansell J, Zappe S, Jiang X, et al. A Novel Whole Blood 
Point-of-Care Coagulometer to Measure the Effect of 
Direct Oral Anticoagulants and Heparins. Semin Thromb 
Hemost 2019;45:259-63. 
80. Harder S, Santos SMD, Krozer V, et al. Surface Acoustic 
Wave-Based Microfluidic Coagulation Device for 
Monitoring Anticoagulant Therapy. Semin Thromb 
Hemost 2019;45:253-8. 
81. Nilsson CU, Strandberg K, Reinstrup P. Warfarin 
monitoring with viscoelastic haemostatic assays, thrombin 
generation, coagulation factors and correlations to Owren 
and Quick prothrombin time. Scand J Clin Lab Invest 
2018;78:358-64. 
82. Gosselin RC, Adcock DM, Bates SM, et al. International 
Council for Standardization in Haematology (ICSH) 
Recommendations for Laboratory Measurement of Direct 
Oral Anticoagulants. Thromb Haemost 2018;118:437-50. 
83. Al Dieri R, de Laat B, Hemker HC. Thrombin generation: 
what have we learned? Blood Rev 2012;26:197-203. 
84. Douxfils J, Morimont L, Bouvy C, et al. Assessment of 
the analytical performances and sample stability on ST 
Genesia system using the STG-DrugScreen application J 
Thromb Haemost 2019. [Epub ahead of print]. 
doi: 10.21037/aob.2019.07.01
Cite this article as: Helin T, Joutsi-Korhonen L, Lassila R. 
Clinical use and laboratory testing of oral anticoagulation 
therapy: experience from Finland. Ann Blood 2019;4:17.
